Liminatus Pharma, Inc. (NasdaqCM: LIMN)
Health Care · Biotechnology · US
$3.04
-19.15% today · -95.0% 1Y
Liminatus Pharma, Inc. (NasdaqCM: LIMN) operates in the Biotechnology industry within the Health Care sector. The company is valued at $4.08M and employs 1 people.
Over the last twelve months the share price has lost 95.0%, trading between 3.01 and 141.50.
Tweenvest scores Liminatus Pharma, Inc. across four factors: quality 16/100, value 24/100. Its strongest factor is value.
LIMN price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $4.08M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -18.06
- Dividend yield
- —
- Beta (5Y)
- 0.75
- 52-week high
- $141.50
- 52-week low
- $3.01
- Avg volume (3M)
- —
- Shares outstanding
- 1.34M
- Employees
- 1
- Next earnings
- —
About Liminatus Pharma, Inc.
Liminatus Pharma, Inc. is an immuno-oncology firm, currently in its clinical development phase, dedicated to pioneering new treatments for cancer. The company's headquarters are located in La Palma, California.
- ISIN
- US53271X2071
- Founded
- 2018
- Listed since
- May 1, 2025
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| NuCana plcNasdaqCM: NCNA | $4.27M | $0.99 | -9.99% |
| Telo Genomics Corp.TSXV: TELO | $4.26M | CA$0.06 | -14.29% |
| Strategic Partners A/SCPSE: STRAP | $4.11M | Dkr655.00 | -2.96% |
| Medicus Pharma Ltd.NasdaqCM: MDCX | $4.11M | $3.25 | 0.00% |
| Enlivex Ltd.NasdaqCM: ENLV | $4.08M | $0.21 | -19.29% |
| Biotron LimitedASX: BIT | $3.88M | AU$0.00 | -20.00% |
| Genetic Analysis ASXSAT: GEAN | $3.82M | Nkr— | — |
| KALA BIO, Inc.NasdaqCM: KALA | $3.67M | $0.19 | -35.40% |
Figures last refreshed Oct 18, 2026.